Table 6.
Relative effects and the 95% credible interval of all pairwise panels for accuracy in early stages based on Bayesian network meta-analysis method.
| A | B | C | D | E | H | I | K | M | |
|---|---|---|---|---|---|---|---|---|---|
| A | 1 | ||||||||
| B | 13.11 (3.63-64.32) | 1 | |||||||
| C | 12.8 (3.52-56.57) | 0.96 (0.59-1.55) | 1 | ||||||
| D | 16.39 (4.52-78.16) | 1.23 (0.74-2.07) | 1.28 (0.78-2.16) | 1 | |||||
| E | 12.53 (3.49-60.5) | 0.95 (0.57-1.59) | 0.99 (0.59-1.65) | 0.78 (0.45-1.29) | 1 | ||||
| H | 2.03 (0.39-11.46) | 0.15 (0.04-0.49) | 0.16 (0.05-0.52) | 0.12 (0.04-0.4) | 0.16 (0.05-0.52) | 1 | |||
| I | 6.41 (1.27-42.42) | 0.49 (0.15-1.51) | 0.5 (0.16-1.59) | 0.39 (0.12-1.27) | 0.51 (0.16-1.6) | 3.22 (0.7-15.51) | 1 | ||
| K | 3.78 (0.7-22.83) | 0.28 (0.08-0.95) | 0.29 (0.09-0.96) | 0.23 (0.07-0.78) | 0.3 (0.08-1.01) | 1.83 (0.39-9.56) | 0.58 (0.12-2.8) | 1 | |
| M | 6.87 (2.07-31.35) | 0.53 (0.35-0.78) | 0.55 (0.37-0.81) | 0.43 (0.27-0.68) | 0.55 (0.35-0.88) | 3.44 (1.15-11.07) | 1.09 (0.37-3.22) | 1.88 (0.6-5.87) | 1 |
A: MMP-9/TIMP-1; B: M-CSF+CA15; C: VEGF + CA 15-3; D: VEGF + M-CSF + CA 15-3; E: VEGF+ M-CSF; H: CA 15.3 + IL-18; I: MSA + B2m; K: TF1+TF2+TF3; M: mammography.